We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fungal Infection Test Measures Gene Response

By LabMedica International staff writers
Posted on 10 Mar 2010
A test being developed will measure how a patient's genes respond to fungal infections. More...
The test will be suitable for very sick or immunocompromised patients, particularly critical care patients.

The early gene-expression test for the fungal pathogen Candida was demonstrated in mice by scientists at Duke University's Institute for Genome Sciences & Policy (Durham, NC, USA). The scientists are gathering human specimens to devise a similar test to be used in humans.

The scientists performed an analysis of gene expression in blood samples of mice that were exposed to Candida albicans and a group of healthy control mice. They studied genes associated with immune response and found 20 sets of 60-80 genes were expressed together. One group of genes in particular distinguished the infected samples from the control samples.

Data were combined from the C. albicans group with data from a group of mice infected with Staphylococcus aureus. Two groups of genes were identified that could distinguish between the three groups of mice (healthy, those with candidemia and those with a staph. infection).

Candidemia in humans often has similar symptoms to other serious bloodstream infections. Discriminating between a bloodstream fungal infection and a bacterial infection using blood culture tests can take 48-72 hours and the results are not always reliable.

"This study provides the basis for development [of] a blood-gene expression test in humans to detect a life-threatening infection earlier than can be done using currently available methods," said Duke University's Prof. Geoffrey Ginsburg, senior author of the study.

People most at risk for Candidemia include patients hospitalized in intensive care units (ICUs), those after abdominal surgery, receiving antibacterial therapies, with central line catheters, and those who are immunosuppressed.

Duke University's scientific team considers the findings as the first step in the production of gene-expression signatures. As Prof. Ginsburg commented, ''This work is also part of a portfolio of blood gene-expression-based tests we are developing to detect viral, bacterial and now fungal infections that will lead to more precise diagnosis and more appropriate therapies for infectious disease."

The findings appeared in the March 3, 2010 edition of the journal Science Translational Medicine.

Related Links:
Duke University's Institute for Genome Sciences & Policy



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.